Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

ERV expression may predict response to immune checkpoint blockade in ccRCC, other solid tumors

Panda A et al. ASCO-SITC, Abstract #104

Publish date:: February 13, 2018

Key clinical point: ERV3.2 expression is associated with immune checkpoint blockade response in ccRCC.

Major finding: ERV3.2 expression was significantly higher in responders vs. nonresponders in two primer sets (P less than .05 and.005).

Study details: A pan-cancer analysis of more 4,900 tumors.

Disclosures: Dr. Ganesan reported that his spouse is employed by Merck and that he is a consultant and/or advisory board member for Novartis, Roche, and Inspirata. He also holds patents with Inspirata.

Citation:

This is how a citation appears

Commentary:

This is how Commentary appears.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Immunotherapy

Immune checkpoint inhibitors don’t increase COVID-19 incidence or mortality, studies suggest,

Personalized cancer vaccine may enhance checkpoint inhibitor activity,

New registry focuses on rheumatic immune-related AEs of cancer therapy,

Tumor neoantigenicity metric improves prediction of response to immunotherapy,

New Toxicity Subscale Measures QOL in Cancer Patients on Checkpoint Inhibitors,